Sandostatin injection, octreotide injection, Sandostatin LAR Depot

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:
❑ *Ambulatory Surgical* ❑ *Home* ❑ *Inpatient Hospital* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Sandostatin SGM – 10/2020

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Criteria Questions:

1. Which drug is being prescribed?
   - ❑ Sandostatin injection ❑ Sandostatin LAR Depot
   - ❑ octreotide acetate injection (generic) ❑ Other _____
2. What is the patient's diagnosis?
   - ❑ Acromegaly
   - ❑ Carcinoid syndrome
   - ❑ Neuroendocrine tumors of the gastrointestinal tract (carcinoid tumors), unresectable or metastatic
   - ❑ Neuroendocrine tumors of the thymus (carcinoid tumors), unresectable or metastatic
   - ❑ Neuroendocrine tumors of the lung (carcinoid tumors), unresectable or metastatic
   - ❑ Neuroendocrine tumors of the pancreas
   - ❑ Neuroendocrine tumors of the adrenal gland
   - ❑ Unresectable meningioma
   - ❑ Thymoma or thymic carcinoma
   - ❑ Congenital hyperinsulinism in an infant/persistent hyperinsulinemic hypoglycemia of infancy (PHHI)
   - ❑ Other _____
3. What is the ICD-10 code? _____

Complete the following section if patient's diagnosis is acromegaly.

4. Is the patient currently on therapy with the requested medication? ❑ Yes ❑ No *If No, skip to #6*
5. How has the patient's IGF-1 level (insulin-like growth factor 1) changed since initiation of therapy? ***Indicate below and no further questions.***
   - ❑ Increased ❑ Decreased or normalized ❑ No change
6. How does the patient's pretreatment IGF-1 level (insulin-like growth factor 1) compare to the laboratory's reference normal range based on age and/or gender?
   - ❑ IGF-1 level is **higher** than the laboratory's normal range
   - ❑ IGF-1 level is **lower** than the laboratory's normal range
   - ❑ IGF-1 level **falls within** the laboratory's normal range
7. Has the patient had an inadequate or partial response to surgery or radiotherapy? *If Yes, no further questions* ❑ Yes ❑ No
8. Is there a clinical reason why the patient has not had surgery or radiotherapy? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Sandostatin SGM – 10/2020

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com